Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2007
In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for July-September 2007. Our data come from Windhover's Strategic Transactions Database.
You may also be interested in...
Just one year ago, Bristol-Myers Squibb's days as an independent entity seemed numbered. But thanks to the resolution of the Plavix crisis, innovative deal-making, and an R&D pipeline surging with specialty-focused products, the company is now thriving. In a free-wheeling Q&A, Bristol's R&D gurus, Francis Cuss and Elliott Sigal, discuss the need for a new kind of biopharma that is specialty-focused and technology agnostic.
Isis and Alnylam have entered a joint venture in microRNA technology and therapeutics called Regulus. The company's first product candidate will be a next-generation antisense therapy against miR122, a microRNA involved in hepatitis C virus replication.
Pharma companies are bullish about biologics, seeing them as at least a partial solution for the pipeline troubles and reimbursement challenges bedeviling the industry. The major question is how best to bring these new biologics capabilities in-house--either piecemeal through a series of smaller acquisitions and licensing deals or in one fell swoop through the acquisition of a player with soup-to-nuts capabilities. Both strategies require delicate post-merger management skills, but many feel acquiring an end-to-end player is a faster, less risky solution to filling the biologics gap. But because few end-to-end biologics players are left for acquisition, in the future it seems likely that Big Pharma will be forced to make a serial acquisition strategy work.